Navigation Links
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
Date:8/12/2008

Additional Resources to Accelerate ENMD-2076 Partnering Efforts

ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has engaged JSB-Partners, a global life sciences advisor, to enhance business development and partnering activities for its lead Aurora A/angiogenesis kinase inhibitor, ENMD-2076.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, orally-active, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 has a unique combination of target activities including cell cycle inhibition (Aurora A), antiangiogenesis (VEGFR, FGFR, PDGFR), and antiproliferative (Flt-3, Src, c-Kit) kinase inhibition. ENMD-2076 has demonstrated substantial 1) dose-dependent efficacy, both as a single agent and in combination with approved therapies, in multiple preclinical models; and 2) tumor regression in breast, colon, leukemia, and other cancers. ENMD-2076 has shown a favorable safety profile in preclinical studies without cardiovascular toxicity. EntreMed has strong intellectual property around the lead compound, ENMD-2076, and over 600 analogs. ENMD-2076 is currently in a Phase 1 study in refractory cancer patients. A Phase 1 study in either multiple myeloma or hematological cancers is planned for the second half of 2008.

"Consistent with our strategy, we have been actively seeking partnership opportunities for our unique, orally-active, selective kinase inhibitor, ENMD-2076. The relationship with JSB-Partners will intensify our partnering activities for ENMD-2076, improving our speed and global outreach," commented Thomas H. Bliss, EntreMed Senior Vice President, Corporate and Business Development. Mr. Bliss continued, "Based on the compound's strong preclinical antitumor activity, favorable safety profile, bioavailability, and multiple mechanisms of action, we believe that ENMD-2076 has significant therapeutic potential in a broad range of tumor types. ENMD-2076 represents an exciting clinical-stage opportunity for the right partner."

About JSB-Partners

JSB-Partners is a global transaction advisory firm with a proven history in creating value for its clients. The partners' broad life science and medical backgrounds also include deep and diverse expertise in financial, commercial, and strategic business transactions at the global level. JSB has extensive and trusted relationships with pharma/biotech clients and shareholders, and a proven partnering process, which allows them to achieve optimal transactions and aligned outcomes for stakeholders. JSB's partners are located in Europe, the United States, and Japan.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

Contact:

Ginny Dunn

Associate Director

Corporate Communications & Investor Relations

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: